[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649914":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":22,"collaborators":25,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":10},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Long-standing Ulcerative Colitis High-risk Cohort",null,"Participants with long-standing UC meeting high-risk criteria (disease duration \\>8\u002F10 years, PSC, family history, or prior neoplasia). All participants undergo a unified surveillance protocol: baseline data collection → fecal sample collection for FIT and FC testing → LCI colonoscopy within 4 weeks regardless of stool test results.",[13],{"name":14,"affiliation":5,"role":15},"Yanbo Yu","PRINCIPAL_INVESTIGATOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"yan zhang","CONTACT","8618769783511","yuyanbo2000@126.com",{"type":15,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yan Zhang, MD","professor of medicine",[26,28,30,32,34],{"name":27,"class":6},"Qilu Hospital of Shandong University (Qingdao)",{"name":29,"class":6},"Zaozhuang Municipal Hospital",{"name":31,"class":6},"Weifang Traditional Chinese Medicine Hospital",{"name":33,"class":6},"Linyi People's Hospital",{"name":35,"class":36},"Shouguang people's Hospital","UNKNOWN","100649914","the-fecal-immunoassay-occult-blood-test-combined-with-calprotectin-sequential-linkage-imaging-endoscopy-screening-strategy-for-monitoring-tumor-changes-associated-with-long-duration-ulcerative-colitis-100649914",false,"NCT07742410","The Fecal Immunoassay Occult Blood Test Combined With Calprotectin Sequential Linkage Imaging Endoscopy Screening Strategy for Monitoring Tumor Changes Associated With Long-duration Ulcerative Colitis","Diagnostic Performance of Fecal Immunochemical Test Combined With Fecal Calprotectin Sequential Linked Color Imaging Endoscopy for Surveillance of Colitis-Associated Neoplasia in Long-standing Ulcerative Colitis: A Multicenter, Prospective Cohort Study","DETECT-UCAN","Inclusion Criteria:\n\n* Age 18-75 years, any gender.\n* Definite diagnosis of ulcerative colitis by clinical, endoscopic, and pathological criteria.\n* Meeting at least one of the following high-risk criteria (with first onset of mucopurulent bloody stool as the starting time): E1\u002FE2 disease duration \\>10 years; E3 disease duration \\>8 years; with primary sclerosing cholangitis (PSC); first-degree family history of colorectal cancer; history of colorectal neoplasia resected.\n* Discontinued any form of glucocorticoids for at least 4 weeks prior to enrollment.\n* In clinical remission at enrollment (stool frequency score \\\u003C3, rectal bleeding score = 0).\n* Able to understand the study, voluntarily participate, and sign written informed consent.\n\nExclusion Criteria:\n\n* Presence of other gastrointestinal diseases or tumors.\n* Severe comorbidities (e.g., cardiopulmonary insufficiency, hepatic or renal failure) that may affect study results or preclude tolerance of endoscopy.\n* Currently taking antiplatelet or anticoagulant medications (aspirin, warfarin, rivaroxaban, etc.).\n* Pregnant or breastfeeding women.\n* History of total or subtotal colectomy.","ALL","18 Years","75 Years",{"count":49,"type":50},250,"ESTIMATED","12 Months","OBSERVATIONAL","Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with an increased risk of colorectal cancer, known as UC-associated neoplasia (UCAN). Current guidelines recommend regular colonoscopy surveillance for long-standing UC patients, but this strategy faces challenges including poor adherence and low neoplasia detection rates. This study aims to evaluate the diagnostic performance of a non-invasive pre-screening strategy combining fecal immunochemical test (FIT) and fecal calprotectin (FC), followed by linked color imaging (LCI) colonoscopy, for detecting UCAN in patients with long-standing UC.\n\nThis is a multicenter, prospective, diagnostic cohort study. Eligible patients with long-standing UC (disease duration \\>8 years for extensive colitis or \\>10 years for left-sided colitis, or with PSC) will undergo FIT and FC testing, followed by LCI colonoscopy within 4 weeks regardless of stool test results. The primary outcome is the diagnostic performance (sensitivity, specificity, PPV, NPV) of combined FIT+FC testing for UCAN, using LCI colonoscopy with histopathology as the reference standard. A total of 250 participants will be enrolled from 6 centers in China. Secondary outcomes include UCAN detection rate, feasibility indicators, patient adherence and acceptability, optimal cut-off values for FIT and FC, and 12-month miss rate.",[55],"Ulcerative Colitis (UC)","NOT_YET_RECRUITING","2026-07-29",{"date":59,"type":60},"2026-08-03","ACTUAL",{"date":62,"type":50},"2026-07-23",{"date":64,"type":50},"2029-12-31",{"name":5,"class":6}]